SPARKLE: a new spark in treating oligorecurrent prostate cancer: adding systemic treatment to stereotactic body radiotherapy or metastasectomy: key to long-lasting event-free survival?
Rans K, Charlien B, Filip A, Olivier H, Julie DH, Céderic D, Herlinde D, Benedikt E, Karolien G, Annouschka L, Nick L, Kenneth P, Carl S, Koen S, Hans V, Ben V, Steven J, Gert M.
Rans K, et al. Among authors: hans v.
BMC Cancer. 2022 Dec 12;22(1):1294. doi: 10.1186/s12885-022-10374-0.
BMC Cancer. 2022.
PMID: 36503429
Free PMC article.
Clinical Trial.